(AOF) – Spineway, specialist in innovative implants for the treatment of severe spinal pathologies (spine), has decided to implement a consolidation of the shares making up its share capital, at the rate of 1 new share against 2,000 old ones. Taking into account the exchange parity adopted, as a result of the consolidation, the number of shares in circulation will be divided by 2,000. The par value of the Spineway share will be increased proportionally to the consolidation parity and will go from 0.002 euros to 4.00 euros.
This grouping aims to reduce the volatility of the Spineway share price and promote its stabilization and thus better reflect the Group’s development prospects.
“This regrouping has no impact on the amount of the share capital, only the par value of the share and, concomitantly, the number of shares in circulation are modified,” explains Spineway.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.